Pulmatrix reports 2021 revenue $5.2M, net loss $20.2M; cash $53.8M; pipeline milestones set

Pulmatrix, Inc.

Revenue $5.2M in 2021 vs $12.6M in 2020; net loss $20.2M vs $19.3M; EPS ($8.63).
Cash $53.8M at Dec 31, 2021; raised $46.75M in 2021; funded into Q1 2024.
Hired Dr. Margaret Wasilewski as CMO; completed 1-for-20 reverse stock split; regained Nasdaq compliance.
Pulmazole Phase 2b in ABPA to start Q1 2023, data mid-2024; PUR3100 Phase 1 in Australia Q3 2022.
PUR1800 Phase 1b met safety endpoint; preclinical tox supports chronic dosing in COPD, asthma, IPF.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.